Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTFields plus Pembrolizumab in Advanced NSCLC
NCT04892472Phase 2Terminated
- Sponsor
- NovoCure
- Start
- Jul 2021
- Primary completion
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by NovoCure. Primary endpoint: Progression Free Survival at 24 months. Started Jul 2021; status: terminated.
Beyond the preview
Go deeper on NCT04892472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04892472.